Last updated on May 2016

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis


Brief description of study

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

Detailed Study Description

Inflammatory bowel diseases, including ulcerative colitis, are chronic relapsing disorders characterized by destructive inflammation and epithelial injury in the gastrointestinal tract. This study will evaluate the efficacy of intravenous (IV) ustekinumab in inducing clinical remission in subjects with moderately to severely active ulcerative colitis.

Clinical Study Identifier: TX5524

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Jo-Anne E. Tiamzon, BS, CCRC

Gastroenterology Associates of Tidewater
Chesapeake, VA USA
  Connect »

Rachel Karlnoski

University of South Florida- South Tampa Center For Advanced Healthcare
Tampa, FL USA
  Connect »